How much do you know about Inspire Sleep Apnea Treatment?

Understanding Inspire Sleep Apnea Treatment: Eligibility, Success Rates, and Side Effects

• Obstructive sleep apnea (OSA) affects a significant portion of the adult population in the United States.
• OSA can cause snoring, breathing interruptions, and daytime sleepiness, and is linked to health risks like heart disease and stroke.
• The Inspire Sleep Apnea Treatment is an upper airway stimulation (UAS) treatment that aims to open the airway during sleep to reduce OSA symptoms.
• The treatment involves implanting a monitoring device in the chest and a nerve stimulator under the chin, which work together to monitor breathing and stimulate tongue movement to clear the airway.
• The Inspire treatment has a success rate of reducing AHI scores by at least 50% and ODI scores by 25% in 75% of participants.
• The Inspire Sleep Apnea Treatment is currently the only internal neurostimulation treatment for OSA approved by the FDA for individuals aged 18 and up.
• Most major US insurance providers, including Medicare, cover Inspire treatment, but costs may vary depending on individual policies.
• Unlike CPAP therapy, which uses pressurized air to keep the airway open, the Inspire treatment uses nerve stimulation.
• Side effects of the Inspire treatment may include temporary tongue weakness, tongue abrasion, mouth dryness, and discomfort from the nerve stimulator.
• Follow-up care following the procedure includes turning on the device 30 days after the procedure and checking the device and settings with a doctor once or twice a year.
• Inspire device users can have MRIs on certain parts of the body, but not on the chest or torso.
• Eligibility for the Inspire Sleep Apnea Treatment is determined by meeting certain requirements, including having moderate to severe OSA, being unable to use or benefit from CPAP therapy, and passing a drug-induced sleep endoscopy.

Understanding Inspire Sleep Apnea Treatment: Eligibility, Success Rates, and Side Effects

• Obstructive sleep apnea (OSA) affects a significant portion of the adult population in the United States.
• OSA can cause snoring, breathing interruptions, and daytime sleepiness, and is linked to health risks like heart disease and stroke.
• The Inspire Sleep Apnea Treatment is an upper airway stimulation (UAS) treatment that aims to open the airway during sleep to reduce OSA symptoms.
• The treatment involves implanting a monitoring device in the chest and a nerve stimulator under the chin, which work together to monitor breathing and stimulate tongue movement to clear the airway.
• The Inspire treatment has a success rate of reducing AHI scores by at least 50% and ODI scores by 25% in 75% of participants.
• The Inspire Sleep Apnea Treatment is currently the only internal neurostimulation treatment for OSA approved by the FDA for individuals aged 18 and up.
• Most major US insurance providers, including Medicare, cover Inspire treatment, but costs may vary depending on individual policies.
• Unlike CPAP therapy, which uses pressurized air to keep the airway open, the Inspire treatment uses nerve stimulation.
• Side effects of the Inspire treatment may include temporary tongue weakness, tongue abrasion, mouth dryness, and discomfort from the nerve stimulator.
• Follow-up care following the procedure includes turning on the device 30 days after the procedure and checking the device and settings with a doctor once or twice a year.
• Inspire device users can have MRIs on certain parts of the body, but not on the chest or torso.
• Eligibility for the Inspire Sleep Apnea Treatment is determined by meeting certain requirements, including having moderate to severe OSA, being unable to use or benefit from CPAP therapy, and passing a drug-induced sleep endoscopy.